Accelerating the pace of innovation in cell and gene therapy – how USP <72> is set to rewrite the rules of sterility testing
With the introduction of new guidances and the endorsement of USP has not only provided a clear support for rapid microbiological methods, but it has also issued a challenge to the wider industry – pushing pharmaceutical companies are encouraged to innovate beyond current expectations by embracing processes that can deliver much faster testing results without compromising on safety and compliance.